NCT05960851View on ClinicalTrials.gov

A Study of LY3871801 in Healthy Asian and Non-Asian Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

August 9, 2023

Primary Completion Date

October 25, 2023

Study Completion Date

October 25, 2023

Conditions

Healthy

Interventions

DRUG

LY3871801

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

90630

Altasciences Clinical Los Angeles, Inc, Cypress

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY